![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 45, 35098-35105, November 10, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of
Received for publication, August 19, 2000
Aggrecan is a complex multidomain macromolecule
that undergoes extensive processing and post-translational
modification. A thorough understanding of the events and signals that
promote translocation of aggrecan through the secretory pathway is
lacking. To investigate which features of the C-terminal G3 region are necessary for successful translocation of the core protein, a number of
deletion constructs based on the chick aggrecan cDNA sequence were
prepared and transiently expressed in COS-1 cells and the natural host,
embryonic chick chondrocytes; stable cell lines were established as
well. The present results clearly establish a precise requirement for
that portion of the G3 C-lectin domain encoded by exon 15 for: (i)
translocation from the endoplasmic reticulum (ER) to the Golgi, (ii)
secretion from the cell, (iii) galactosylation of chondroitin sulfate
(CS) chains, (iv) generation of
Ca+2-dependent galactose binding ability.
Furthermore, in the absence of this subdomain there is excess
accumulation in the ER of expression products leading to a
stress-related response involving the chaperones Grp78 and protein
disulfide isomerase, followed by degradation via a ubiquitin-proteosome
pathway. All of these events in the model system faithfully mimic the
naturally occurring nanomelic mutant, which also elicits a
ubiquitin-mediated degradation response due to the accumulation of the
truncated core protein precursor. This study represents the first
report of the mode of degradation of overexpressed or misfolded
proteoglycans and suggests that, although proteoglycans follow
different glycosylation pathways from other glycoproteins, they are
monitored by an ER surveillance system similar to that which detects
other misfolded proteins.
Aggrecan, the major proteoglycan of the cartilage extracellular
matrix, contains two globular domains in the N-terminal portion, G1 and
G2, and one C-terminal globular domain, G3. Between the G2 and G3
globular domains, glycosaminoglycan chains
(GAGs)1 are covalently
attached to an extended core protein. Functionally, it is well
established that the G1 domain is responsible for interaction with
hyaluronan in the extracellular matrix. The C-terminal G3 domain has
been implicated in synthesis and maturation of aggrecan, because its
absence is associated with the avian chondrodystrophy, nanomelia. The
nanomelic chick bears a mutation in the aggrecan gene that introduces
an early stop codon into the translated sequence, resulting in
synthesis of a truncated core protein, which is neither glycosylated
nor secreted by chondrocytes (1). The mutant precursor is modified by
addition of N-linked oligosaccharides and the chondroitin sulfate chain initiating xylose, but does not acquire mature CS chains,
consistent with the conclusion that it progresses no further than the
endoplasmic reticulum (ER) in the secretory pathway (2). These studies
suggested a previously unrecognized role for the C-terminal globular
domain: that it might contain recognition or retention signals or that
proper folding of this specific domain, which may involve interactions
with molecular chaperones, is necessary to effect exit of the
entire core protein precursor from the ER. The latter mechanism would
place the nanomelic mutant into the important category of folding
abnormalities, which are increasingly being found to be responsible for
genetic diseases, such as cystic fibrosis (3).
In attempting to determine how the accumulation of aggrecan in the ER
is related to the role of the G3 domain in intracellular trafficking of
proteoglycans, a few studies have expressed G3 constructs in host cells
and assessed their behavior. Luo et al. (4) showed that the
G3 domain is more efficient in facilitating the secretion of a CS
sequence than is the N-terminal G1 domain. When exon deletion
constructs were used to determine which domains were responsible for
the secretion of the G3 domain, only proteins lacking the C-lectin
subdomain were not secreted, whereas those lacking the EGF- and
CRP-like subdomains were normally passaged; oddly, one construct (GAG5)
lacking EGF, lectin-like, and CRP was also secreted (5). More
recently, each lone protein module, lectin-, CRP- or EGF-like, was
shown to facilitate the translocation and secretion of a CS sequence
(6). The discrepancies between these independent studies are not
readily explained and none relate directly to the naturally occurring
mutation in the nanomelic chick, which prevents translocation and
processing of the aggrecan core protein. Therefore, we have initiated
studies to better define the intracellular processing of aggrecan,
focusing on the G3.
In eucaryotic cells the ER has the inherent function of ensuring that
only correctly folded and assembled proteins are forwarded to their
destinations. The term "quality control" has been adopted to
describe the process of conformation-dependent molecular
sorting of newly synthesized proteins in the ER (7). Most commonly, misfolded or incompletely assembled proteins are retained in the ER and
eventually degraded. A number of mechanisms detailing how this is
accomplished have been elucidated over the past decade, and most
involve ER chaperones or folding enzymes (7).
Furthermore, under conditions that overwhelm the ER surveillance system
and promote intracellular association of substrate proteins with ER
chaperones like calnexin and BiP, accumulation of misfolded or aberrant
proteins leads to targeting of those proteins for subsequent
degradation in the cytosol, mediated by the ubiquitin-proteosome
pathway (8). At present little is known about normal intracellular
degradation of proteoglycan precursors or about the surveillance system
that recognizes and deals with defective products. Thus, studies have
also been initiated to characterize the degradative pathways and
determine whether proteosomes are involved in aggrecan turnover.
Materials--
Oligonucleotides were made with an Applied
Biosystems 3808 DNA synthesizer. The following reagents for biochemical
and molecular cloning experiments were of the highest quality available
and purchased from commercial vendors: restriction endonucleases from New England BioLabs, Taq polymerase from PerkinElmer Life
Sciences, pTargeT mammalian expression vector and T4 DNA ligase from
Promega, DTSSP (3,3-dithiobis(sulfo-succinimidyl propionate)) and
D-galactose affinity resin from Pierce, anti-Grp78 and
anti-ubiquitin antibodies from Stress Gen Biotechnologies, anti-PDI
antibody from Affinity Bioreagents, anti-Golgi 58k protein from Sigma.
Synthesis of Deletion Constructs--
The inserts for plasmid
constructs N1, N2, N3, N4, N5, and N6 (Fig. 1A) were made by
PCR using the full-length NC construct as a template, each using the
5'-primer, NANO 1, TTCTGCTCTAAACCGGATCGATCCCTCGAG. The NC construct
contains the chick aggrecan signal peptide exon, a portion of the CS
exon beginning at nucleotide 3837 which encompasses the S103L epitope,
all of the G3 domain exons, and a portion (78 base pairs) of the
C-terminal tail (9). The following 3'-primers were employed for the PCR
reactions: N1 (GCTCTAGAGCGTCTTCTGTAGTGGGTCCCAG), N2
(GCTCTAGAGCGTCGATCTCACACAGGTC), N3
(GCTCTAGAGCGCTGTTCACAAATTCTTG), N4
(GCTCTAGAGCCAGCGAGTGTCCATCAGA), N5 (GCTCTAGAGCAACTGTTCCCTTCTTGCA), and N6 (GCTCTAGAGCGGGGTTTGTGCAGGATAT). XhoI and
XbaI sites at the 5'- and 3'-ends, respectively, of the
inserts were introduced at the end of the amplified fragments via the
primers used. Inserts were subcloned into the pTargeT expression
vector. Clones were screened for the correct inserts by plasmid DNA
isolation and subsequent XhoI-XbaI digestion for
2 h. Automated sequencing of the various constructs was done to
confirm the appropriate orientation of the inserts and exclude PCR
artifacts. DNA was purified using the Qiagen Plasmid Maxiprep kit.
Cell Culture and Transfection--
Chondrocytes were prepared
from sterna of 15-day-old chick embryos and grown in F12 media with
10% fetal calf serum supplemented with gentamicin at a density of
5 × 106 cells per dish as described previously (10).
COS-1 cells were grown in Dulbecco's modified Eagle's medium with
10% fetal calf serum at 37 °C and 5% CO2. All
transfections were performed using the calcium phosphate method (11,
12). Chondrocytes were trypsinized for 5 h before transfection and
replated. COS-1 cells and chondrocytes were transfected using 10 µg
of plasmid DNA. Stably transfected COS-1 cells were selected using 500 µg/ml geneticin (G418 sulfate), and cell lines were then maintained
in media containing 250 µg/ml geneticin.
Immunoprecipitation and Western Blot Analysis--
Media and
cells scraped in immunoprecipitation buffer (100 mM caproic
acid, 500 mM NaCl, 1 mM EDTA, 1% Nonidet P-40,
and 0.5% sodium deoxycholate, 10 mM Tris-HCl, pH 8) were
immunoprecipitated with the S103L antibody (13). Protein A-Sepharose
beads (20 mg) resuspended in phosphate-buffered saline were incubated
with 60 µg of rabbit anti-rat IgG for 1 h at 4 °C, washed
with phosphate-buffered saline, and incubated with S103L antibody (100 µg) for 1 h at 4 °C. After washing with immunoprecipitation
buffer, the beads were added to the samples and incubated overnight at
4 °C. The unbound material was removed, and the immunoadsorbed beads
were then extensively washed with the corresponding immunoprecipitation buffer. After a final wash with chondroitinase digestion buffer (5 mM EDTA, 100 mM Tris, pH 7.4, 1 mM
phenylmethylsulfonyl fluoride, 10 mM
N-ethylmaleimide and 0.36 mM pepstatin), half of
each immunoprecipitate was treated with 0.5 unit/ml chondroitinase ABC
at 37 °C for 4 h. Treated and untreated beads were incubated in
sample buffer at 100 °C for 7 min. The eluates were analyzed by
SDS-PAGE using 3.5-6% resolving gels.
Gel bands were electrotransferred to nitrocellulose at 150 mA
overnight. After blocking nonspecific protein binding with 6% BSA in
112 mM NaCl, 125 mM borate buffer, pH 8.5 (BBS), nitrocellulose membranes were incubated in S103L
hybridoma-conditioned medium, 3% BSA in BBS. Following a BBS wash, the
blots were incubated with horseradish peroxidase-conjugated anti-rat
IgG diluted 1:1000 in BBS with 3% BSA. After washing again with BBS,
bound antibody was visualized using the ECL system (Amersham Pharmacia Biotech).
Sugar Nucleotide Radiolabeling of Semi-permeable
Cells--
Stably transfected cell lines were made semipermeable using
the permeabilization procedure of Beckers et al. (14) as
modified by Kearns et al. (15). Briefly, cells were
incubated in hypotonic buffer (10 mM HEPES, 15 mM KCl, pH 7.2) for 10 min at 4 °C. The buffer was
replaced with breaking buffer (50 mM HEPES, 90 mM KCl, pH 7.2), and cells were sheared from the dishes
using a rubber policeman. Cells were pelleted at 1000 × g and resuspended in breaking buffer and incubated with 4 µCi/ml UDP-xylose, 2.5 µCi/ml UDP-galactose, or 250 µCi/ml
Tran35S-label for 1 h at 37 °C. Labeled core
proteins were immunoprecipitated and deglycosylated as described above.
For autoradiography, blots or gels were incubated in amplifying
solution (Amersham Pharmacia Biotech) for 20 min, dried in a gel dryer,
and then processed for autoradiography (30 days, Galactose Affinity Chromatography--
Immobilized
D-galactose affinity chromatography was performed as
described previously (16). Cells were sheared from the dishes using a
rubber policeman in hypotonic buffer and sonicated. Media and cell
extracts were dialyzed against loading buffer consisting of 125 mM NaCl, 20 mM imidazole-HCl, pH 7.8, and 25 mM CaCl2, then passed over a column packed with
2 ml of D-galactose resin (Pierce), equilibrated in the
same buffer. Elution was completed in eight fractions using 64 ml of
loading buffer (0.5 ml/min.). The column was rinsed between trials with
10 ml of buffer containing 2 mM EDTA substituted for
CaCl2. Fractions were dialyzed against 5 mM
Tris, pH 7.4, lyophilized, and resuspended in 50 µl of chondroitinase digestion buffer. All fractions were treated with 0.5 unit/ml chondroitinase ABC and 0.25 unit/ml keratanase at 37 °C for
4 h. Fractions were subsequently separated on 5%
SDS-polyacrylamide gels and Western blotted using S103L as the primary
antibody as described above.
Immunocytochemistry--
Permanently transfected COS-1 cells
were fixed with 4% paraformaldehyde and 0.02% glutaraldehyde and
processed for indirect double immunofluorescence. The rat monoclonal
antibody S103L was used to detect the expressed truncated protein
products, and anti-Grp78 and anti-Golgi 58,000-dalton protein served as
markers of endoplasmic reticulum and Golgi, respectively.
A series of deletion constructs based on the chick aggrecan
sequence (1) were produced in the pTargeT expression vector (Fig.
1A). The parent sequence (NC)
consisted of a portion of the CS domain, which included the S103L
binding site; the EGF1 subdomain encoded by exon 13; the three
subdomains of the C-lectin region, each encoded by exons 14, 15, and
16; the CRP-like domain encoded by exons 17 and 18; and a portion of
the C-terminal tail (9). Each of these domains starting with the
C-terminal tail was consecutively deleted from the 3'-end, until only
the CS region remained, yielding six truncated species of the G3
domain. Incorporation of the naturally occurring S103L recognition site
as a tool to follow the expressed proteins obviated the necessity of an
artificial marker (e.g. His-tag), which might cause
anomalous results (17, 18). Each construct was individually transfected
into COS-1 cells as well as embryonic chick chondrocytes. Transiently
transfected cultures of COS-1 cells produced fully glycosylated
proteoglycans in the culture media from constructs NC, N6, N5, and N4
as evident from the molecular weight shift observed after
deglycosylation with chondroitinase (Fig. 1B). In contrast,
the N3, N2, and N1 (not shown) constructs yielded almost no processed
product in the media, although transfection was successful, as
demonstrated by the expression of the intracellular core protein
products recovered from the cell extracts. Note that N4 shows an
intermediate phenotype, because, although it expresses a significant
amount of intracellular precursor, the amount of product found in the
media is reduced compared with that for NC-transfected cells. Also note
that our results contrast with previous observations that any globular domain in the C terminus will promote translocation (6), because our N2
construct, which contains a full FGF domain, is not secreted. These
results were then confirmed and extended to determine the minimal
requirements for aggrecan processing and secretion.
To ensure that a similar situation pertains to the cells that produce
major amount of aggrecan core protein in vivo,
i.e. chondrocytes, transient transfections were performed in
chick sternal chondrocyte cultures (Fig.
2). Chondrocytes transfected with empty
plasmid secreted normal mature aggrecan into the culture medium, as
evidenced by a >400-kDa S103L-reactive band (arrow), which
appeared only after deglycosylation with chondroitinase ABC (Fig. 2,
EV). This band is observed in all transfected chondrocyte lines analyzed, indicating that normal aggrecan processing and secretion occurs in the presence of the expression vector and derived
constructs. The NC and N4 lane
Role of the C-terminal G3 Domain in Sorting and Secretion of
Aggrecan Core Protein and Ubiquitin-mediated Degradation of Accumulated
Mutant Precursors*
,
,
, and
§¶
Pediatrics and
§ Biochemistry & Molecular Biology, Committee on
Developmental Biology, The University of Chicago, Chicago, Illinois
60637
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
70 °C).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (42K):
[in a new window]
Fig. 1.
Structure and expression of G3
constructs. A, diagram of aggrecan genomic structure
and constructs designed to study G3 function in trafficking.
B, expression and secretion of G3 deletion constructs
expressed in COS-1 cells. COS-1 cells were transiently transfected with
a series of deletion constructs shown in A using the calcium
phosphate method. After 24 h in culture the medium and cell
extracts were immunoprecipitated using the S103L antibody and not
treated (
) or treated (+) with chondroitinase ABC. The upper
panel shows immunoprecipitations from media and the lower
panel those from cell extracts after SDS-PAGE and Western blot
analysis with S103L antibody. The N1 construct (not shown) results were
similar to the N2 construct.
/+ pairs (Fig. 2, Media) show that these constructs (asterisk) are expressed and
secreted, mostly in a glycosylated state. In contrast, no
construct-product bands are present in the Fig. 2 N3
/+ lanes.
Extracts of transfected chondrocytes (Fig. 2, Cells)
contained unprocessed, native aggrecan as shown by the >400-kDa bands
in the untreated lanes (arrowhead) as well as greater
amounts of mature, glycosylated aggrecan in the treated lanes
(arrow). The increase in the amount of normal aggrecan seen
after deglycosylation suggests that three populations are present in
the extracts: unprocessed, processed but not yet secreted, and secreted
but attached to the cell surface. The latter fraction may be bound to
cell-associated HA via the G1 domain; all of the constructs lack G1
domains and could not so attach. In contrast to the normal protein, the
cell extract plasmid-expression products (Fig. 2, Cells,
asterisk) show little evidence of processing. A small amount
of slightly larger product may appear post-deglycosylation for
constructs NC and N4, whereas no change is evident for construct N3.
The major outcome of these experiments is that, although the N3
construct product clearly is synthesized in transfected chondrocytes, there is little or no secretion of the truncated N3 protein and no
indication that it is glycosylated.

View larger version (57K):
[in a new window]
Fig. 2.
Expression and secretion of G3 deletion
constructs expressed in primary chondrocyte cultures. E14 sternal
chondrocyte cultures were transiently transfected with NC, N4, and N3
constructs and empty vector (EV) using the calcium phosphate
method. After 24 h in culture the medium and cell extracts were
immunoprecipitated using the S103L antibody and not treated (
) or
treated (+) with chondroitinase ABC. The upper panel shows
immunoprecipitations from media and the lower panel those
from cell extracts after SDS-PAGE and Western blot analysis with S103L
antibody. The arrow indicates endogenous aggrecan. The
arrowhead indicates the intracellular endogenous aggrecan
precursor associated with the cell. The asterisks indicate
S103L-positive expressed core proteins.
To ascertain where each precursor protein arrests in the processing
pathway, stable cell lines prepared for N4 and N3 constructs were
permeabilized, allowing labeled precursors of proteoglycan synthesis,
e.g. UDP-xylose and UDP-galactose, to be incorporated into
nascent core protein. Comparing the precursor-specific levels of
[35S]methionine labeling in each of the expressed
products, it is seen that the accumulated N3 core protein incorporates
xylose but not galactose (Fig. 3). In
contrast, the N4 core protein incorporates both xylose and galactose,
indicating that the N4/N3 truncation interval is crucial for
galactosylation. Previous studies have shown that these two
glycosyltransferase activities are localized in different compartments
(15, 19). Note that galactosylation in N4-expressed protein is evident
after chondroitinase treatment, in agreement with the observations that
xylosylation is a rate-limiting step in GAG biosynthesis and that,
after translocation of the core protein to the Golgi, successive
reactions proceed quickly without allowing observation of partial
intermediate forms (10). The present results imply that, until the
precursor is translocated from the xylosylation-competent compartment
to the next one, the core protein cannot be galactosylated, and that
translocation requires information inherent in the second lectin exon.
The biochemical localization of the various truncated species was
confirmed by immunocytochemistry using the S103L antibody to stain
stably transfected COS-1 cells. In NC- and N4-expressing cells, very
little intracellular-expressed product was detected, and that which was
present appeared more Golgi-localized as confirmed by double staining
with the anti-Golgi 58k protein (Fig. 4,
NC and N4). The truncated N3 product localized to
the ER and ER-Golgi intermediate compartment as indicated by its
similar distribution with the ER marker, Grp78 (Fig. 4, N3), thus confirming the biochemical evidence that deletion of the second
lectin domain leads to disruption of the CS biosynthetic pathway.
|
|
To determine whether the C-lectin subdomain has functional properties
that contribute to the G3 routing specificity, we examined the
lectin-binding ability of the various constructs on galactose affinity
columns. Culture media and cell extracts from NC, N4, and N3 stable
cell lines were loaded onto a galactose affinity column (Fig.
5), as described previously (16). The
Ca+2-dependent affinity for galactose was
determined by the retention of the protein constructs on the column. No
binding to the column was observed with any constructs in the absence
of Ca+2 (data not shown). As expected, the NC core protein
released into the culture medium as well as that associated with the
cells, binds efficiently to the galactose column. N4 core protein
released to the medium or from cell extracts also binds to the column, although not as efficiently as NC. In contrast, the N3 core protein, which lacks two thirds of the lectin-like domain and remains
intracellular (see Fig. 5, Cell extract), does not
bind to the galactose column. These results directly correlate the
acquisition of Ca+2-dependent galactose-binding
ability, which presumably reflects the presence of a specific
structural motif, with intracellular G3 routing. It should be noted
that the lectin-like domain contains 6 cysteine residues, 3 in exon 14, none in exon 15 and 3 in exon 16. Thus unpaired cysteines are not
responsible for the misfolded lectin-like domain, because both the N3
and N4 constructs contain the same number of cysteines.
|
Using the stably transfected cell lines for NC, N4, and N3, we
established that a cellular response to protein misfolding in the ER is
triggered in the cells expressing the N3 construct. Fig.
6 shows that the ER resident proteins
Grp78 (BiP) and PDI (protein disulfide isomerase) coprecipitate with
S103L-reactive intracellular truncated N3 core protein, but not with
S103L-positive NC or N4 core protein. We were also able to
coprecipitate PDI with the NC core protein if the cells were
permeabilized and incubated with DTSSP prior to immunoprecipitation
(data not shown), indicating that the PDI chaperone may participate in
the normal folding of the G3 domain as well. The multiple species
observed in the overloaded gels of the S103L immunoprecipitates from
the transfected cell lines (Fig. 6, S103L) led us to
ascertain whether the misfolded N3 core protein is degraded and being
targeted for removal via the ubiquitin-proteosome pathway. To this end,
we first determined whether the core protein is a substrate for
ubiquitination by immunoprecipitating N3, N4, and NC core proteins from
cell extracts and preparing Western blots probed with anti-ubiquitin as
primary antibody. Fig. 7A
shows that N3 core protein is ubiquitinated (arrowhead),
suggesting that the ubiquitin-proteosome pathway is involved in the
degradation of this ER-accumulated, truncated proteoglycan core
protein. When larger amounts of cell extracts were immunoprecipitated
(Fig. 7B) some ubiquitination can also be detected
associated with the NC and N4 core proteins, which may be the
consequence of overwhelming the ER surveillance system in the
overexpressing cell lines. Furthermore, expression of
poly-ubiquitinated N3 core protein occurs, as indicated by the presence
of higher molecular weight species of S103L-positive N3 core protein
(Fig. 7B, arrowhead). To determine whether the
truncated aggrecan core protein expressed in the nanomelic chick
undergoes a similar fate, an experiment using cartilage protein from
wild type and nanomelic chicks was performed. In the nanomelic chick,
the accumulated intracellular core protein is ubiquitinated (Fig.
7C), whereas the aggrecan core protein from normal cartilage
also shows some level of ubiquitination, suggesting that the
ubiquitin-proteosome system is involved both in removal of the
ER-accumulated, nanomelic precursor, as well as in the normal
processing of misfolded aggrecan core protein.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
From our studies, which elucidated the mutation in the nanomelic chick, it was learned that not only was there a complete lack of aggrecan in the mutant extracellular matrix, there was also an accumulation of a truncated, partially processed precursor in the chondrocyte ER, leading to the hypothesis that the deleted G3 domain was involved in the intracellular maturation and secretion process of this proteoglycan (1, 2). In the present study, we focused mainly on: (i) identifying the minimal alteration from the native structure tolerated before aggrecan processing and secretion are affected, (ii) elucidating the pathway and players involved in the early steps of processing, (iii) investigating whether the unnatural accumulation of unprocessed core protein induces a stress-related response, and (iv) determining the mode of degradation of the ER-accumulated product.
To examine the importance of the G3 domain for successful translocation from the ER to the ensuing compartments of the secretory pathway, a series of deletion constructs based on the chick sequence were prepared and tested on model cell lines (COS-1 cells) as well as on cell types that predominantly manufacture aggrecan (primary chick chondrocytes). The latter is important, because it is known that the secretory pathway is differentiated in specific cell types and it is therefore not assured that a protein will fold properly in all cell types (7). Perhaps this explains some of the unusual findings of the two previous studies, both of which were done in non-chondrocytic cell lines (5, 6). Although not differing qualitatively, our studies do indicate that chondrocytes are much more efficient in processing the constructs than COS-1 cells, highlighting the presence of a more highly developed or specific system for processing this complex product in chondrocytes.
The translocation-competence properties of the G3 subdomains were then assessed by an exon-by-exon dissection of the G3 domain followed by assays for compartmental transfer, functionality, and modes of degradation. Experiments designed to determine what is recognized in the G3 domain that triggers forward transport indicate that peptide sequence N-terminal to and including the second C-lectin subdomain is required for intracellular translocation of the chick aggrecan constructs (Fig. 2), because there was abundant product secreted into the media for the N4 construct (which is missing the last exon of the lectin domain) and no secretion for the N3 construct (missing the last two lectin exons). That there is a distinct recognition element encoded by the middle lectin-like exon required for movement out of the ER and further steps of glycosylation was determined by defining the ability of the N3 and N4 constructs to be xylosylated and galactosylated. We previously developed this methodology using semipermeable cells and direct labeling with the immediate nucleotide precursors to define the topography (location and organization) of the numerous glycosyltransferase reactions required for synthesis of CS chains on proteoglycans (15). The present results indicate that the N3 construct indeed remains localized to the ER compartment, because only xylose was incorporated into it, whereas the N4 construct presumably was competent to proceed to the next series of glycosyltransferase reactions exemplified by galactose addition in the Golgi compartment. That the presence of a structural motif so clearly demarcates the translocation from late ER to cis-Golgi, as illustrated by lack of galactosylation, suggests a requirement for this motif in the folding process of the core protein into a conformation that is allowed to exit the ER surveillance apparatus (7, 20). In fact, part of this surveillance system may be the CS-chain-initiating xylosyltransferase, which has been hypothesized to play a role in processing and translocation from the ER of glycosylated proteoglycans such as aggrecan (21).
Also suggestive of a functional conformation imposed on the aggrecan core protein by the second lectin domain is the observed ability to generate a galactose-binding motif. To determine whether the C-lectin subdomain has functional properties that contribute to the G3 routing specificity, we examined the lectin-binding ability of the various expressed proteins on galactose affinity columns. The expressed and secreted N4 product was fully capable of calcium-dependent binding to a galactose column, whereas N3 was not, indicating that the second but not the third C-lectin domain exon is required to generate a galactose binding motif. These results are surprising, because the structural basis for galactose recognition by C-type animal lectins described in the literature is mainly localized in the third exon of this domain (22-24); thus in the absence of the third exon, an alternative galactose-binding site may be generated that allows some calcium-dependent binding ability to be maintained. These C-type carbohydrate recognition domains (CRDs) have been extensively studied in the aggrecan core protein where Ca+2-dependent sugar binding by this region has been demonstrated (16, 25). It has been speculated that this sugar binding ability is related to organization of the proteoglycan in the extracellular matrix. At the least, our results indicate that acquisition of this common structural motif is required for translocation from the ER to the Golgi and further processing of the core protein, and perhaps for later functions in the extracellular matrix as well. Although these results suggest that a folding defect occurs that does not allow further processing of the core protein when the second and third exons of N3 are absent, it is also possible that, as has been described in other instances (26, 27), the selective incorporation of the core protein into COPII vesicles, which bud off from the ER, is regulated by binding of small molecules to the CRD domain. Although speculative at present, it remains an attractive possibility in light of the fact that this set of core proteins should be directed to a subset of specific glycosyltransferases in the Golgi and that the truncated products that do move forward in the secretion pathway maintain a functional CRD domain.
It is well established that the intracellular accumulation of abnormally folded or aggregated protein activates the cellular stress response, often leading to attenuation of the cell's ability to tolerate subsequent stress and thus to premature cell death via apoptosis (28). Using stably transfected cell lines, which accumulate the modified aggrecan G3 constructs in the ER, we examined whether a stress response is mounted, as has been shown for other disease processes (7). To verify that certain chaperones or folding factors (both known and novel) participate in the quality control of aggrecan processing in the ER, co-immunoprecipitation experiments with S103L followed by Western blots with antibodies to Grp78 and PDI indicate that these two chaperones were co-immunoprecipitated with accumulated N3 precursor. These associations may result from an effort of the surveillance system to refold the misfolded N3 core protein or from a hydrophobic motif being exposed in the truncated N3 construct that promotes a prolonged interaction with these chaperones. Because PDI can also be immunoprecipitated with NC and N4 core proteins after cross-linking, it is possible that this chaperone is involved in the normal processing of this core protein as well. These results suggest that, although proteoglycan core proteins follow quite different glycosylation pathways from other glycoproteins, they are monitored by an ER surveillance system similar to that which detects other misfolded proteins.
Accumulation of misfolded or aberrant proteins can also lead to targeting of those proteins for subsequent degradation in the cytosol mediated by the ubiquitin-proteosome pathway (8, 20). Co-immunoprecipitation experiments demonstrated specific ubiquitination of both the N3 product and the truncated nanomelic aggrecan, providing initial evidence for proteosomal degradation of aberrant proteoglycan core proteins. The fact that ubiquitination is also observed with the NC and N4 core proteins, as well as with the normal aggrecan core protein, suggests that the ubiquitin-proteosome pathway is the normal processing route for overexpressed or misfolded aggrecan core protein in the ER. However, in the N3-expressing cell line ubiquitination occurred at higher levels, as indicated by the detection of a ladder of ubiquitinated N3 core proteins, even in the absence of proteosome inhibitors (8).
Lastly, the phenotypic characteristics of the N3 (and further-deleted)
generated proteins are comparable to the behavior of the truncated
aggrecan core protein expressed in the nanomelic mutant, at both the
biochemical and trafficking levels, because it has been established
that the nanomelic aggrecan core protein is halted in the ER
compartment where it is xylosylated but not further processed (1, 29).
In the present work we have shown that the abnormally accumulated
product in the nanomelic chondrocyte is likely dealt with via the
ubiquitin-proteosome pathway, as is the accumulated core protein in the
N3 expressing cell lines. It also could be predicted that concomitant
with degradation there is a stress response elicited in the nanomelic
chondrocyte contributing to the overall phenotype of the mutant. Future
studies will address this possibility.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Judy Henry for cell culture, Glenn Burrell for manuscript preparation, and James Mensch for helpful discussion and manuscript review.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants AR-19622 and HD-09402 (to N. B. S.) and Training Grant HL-07237 and by a Fellowship from the Markey Program in Molecular Medicine (to E. W. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Dept. of Pediatrics, University of Chicago, 5841 S. Maryland Ave., MC 5058, Chicago, IL 60637. Tel.: 312-702-6426; Fax: 312-702-9234; E-mail: n-schwartz@uchicago.edu.
Published, JBC Papers in Press, August 25, 2000, DOI 10.1074/jbc.M00758200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: GAG, glycosaminoglycan chain; CS chain, chondroitin sulfate; ER, endoplasmic reticulum; EGF, epidermal growth factor; CRP, complement regulatory protein; DTSSP, 3,3-dithiobis(sulfo-succinimidylpropionate); PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis; BSA, bovine serum albumin; PDI, protein disulfide isomerase; CRD, C-type carbohydrate recognition domain.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Li, H., Schwartz, N. B., and Vertel, B. M. (1993) J. Biol. Chem. 268, 23504-23511 |
| 2. | Vertel, B. M., Grier, B. L., Li, H., and Schwartz, N. B. (1994) Biochem. J. 301, 211-216 |
| 3. | Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., and Welsh, M. J. (1992) Nature 358, 761-764 |
| 4. | Luo, W., Kuwada, T. S., Chandrasekaran, L., Zheng, J., and Tanzer, M. L. (1996) J. Biol. Chem. 271, 16447-16450 |
| 5. | Zheng, J., Luo, W., and Tanzer, M. L. (1998) J. Biol. Chem. 273, 12999-13006 |
| 6. | Day, J. M., Murdoch, A. D., and Hardingham, T. E. (1999) J. Biol. Chem. 274, 38107-38111 |
| 7. | Ellgaard, L., Molinari, M., and Helenius, A. (1999) Science 286, 1882-1888 |
| 8. | de Virgilio, M., Weninger, H., and Ivessa, N. E. (1998) J. Biol. Chem. 273, 9734-9743 |
| 9. | Li, H., and Schwartz, N. B. (1995) J. Mol. Evol. 41, 878-885 |
| 10. | Campbell, S. C., and Schwartz, N. B. (1988) J. Cell Biol. 106, 2191-2202 |
| 11. | Pirok, E. W., III, Li, H., Mensch, J. R., Jr., Henry, J., and Schwartz, N. B. (1997) J. Biol. Chem. 272, 11566-11574 |
| 12. | Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY |
| 13. | Krueger, R. C., Jr., Hennig, A. K., and Schwartz, N. B. (1992) J. Biol. Chem. 267, 12149-12161 |
| 14. | Beckers, C. J., Keller, D. S., and Balch, W. E. (1987) Cell 50, 523-534 |
| 15. | Kearns, A. E., Vertel, B. M., and Schwartz, N. B. (1993) J. Biol. Chem. 268, 11097-11104 |
| 16. | Halberg, D. F., Proulx, G., Doege, K., Yamada, Y., and Drickamer, K. (1988) J. Biol. Chem. 263, 9486-9490 |
| 17. | Ledent, P., Duez, C., Vanhove, M., Lejeune, A., Fonze, E., Charlier, P., Rhazi-Filali, F., Thamm, I., Guillaume, G., Samyn, B., Devreese, B., Van Beeumen, J., Lamotte-Brasseur, J., and Frere, J. M. (1997) FEBS Lett. 413, 194-196 |
| 18. | Geoghegan, K. F., Dixon, H. B., Rosner, P. J., Hoth, L. R., Lanzetti, A. J., Borzilleri, K. A., Marr, E. S., Pezzullo, L. H., Martin, L. B., LeMotte, P. K., McColl, A. S., Kamath, A. V., and Stroh, J. G. (1999) Anal. Biochem. 267, 169-184 |
| 19. | Vertel, B. M., Walters, L. M., Flay, N., Kearns, A. E., and Schwartz, N. B. (1993) J. Biol. Chem. 268, 11105-11112 |
| 20. | Wickner, S., Maurizi, M. R., and Gottesman, S. (1999) Science 286, 1888-1893 |
| 21. | Schwartz, N. B. (1995) Trends Glycosci. Glycotechnol. 7, 429-445 |
| 22. | Brissett, N. C., and Perkins, S. J. (1998) Biochem. J. 329(Pt 2), 415-424 |
| 23. | Iobst, S. T., and Drickamer, K. (1994) J. Biol. Chem. 269, 15512-15519 |
| 24. | Iobst, S. T., Wormald, M. R., Weis, W. I., Dwek, R. A., and Drickamer, K. (1994) J. Biol. Chem. 269, 15505-15511 |
| 25. | Kolatkar, A. R., and Weis, W. I. (1996) J. Biol. Chem. 271, 6679-6685 |
| 26. | Aridor, M., and Balch, W. E. (2000) Science 287, 816-817 |
| 27. | Rivera, V. M., Wang, X., Wardwell, S., Courage, N. L., Volchuk, A., Keenan, T., Holt, D. A., Gilman, M., Orci, L., Cerasoli, F., Jr., Rothman, J. E., and Clackson, T. (2000) Science 287, 826-830 |
| 28. | Zhivotovsky, B., Burgess, D. H., Vanags, D. M., and Orrenius, S. (1997) Biochem. Cell Biol. 230, 481-488 |
| 29. | Vertel, B. M., Walters, L. M., Grier, B., Maine, N., and Goetinck, R. F. (1993) J. Cell Sci. 104, 939-948 |
This article has been cited by other articles:
![]() |
D. Ray, E. C. Osmundson, and H. Kiyokawa Constitutive and UV-induced Fibronectin Degradation Is a Ubiquitination-dependent Process Controlled by beta-TrCP J. Biol. Chem., August 11, 2006; 281(32): 23060 - 23065. [Abstract] [Full Text] [PDF] |
||||
![]() |
N.-S. Seo, A. M. Hocking, M. Hook, and D. J. McQuillan Decorin Core Protein Secretion Is Regulated by N-Linked Oligosaccharide and Glycosaminoglycan Additions J. Biol. Chem., December 30, 2005; 280(52): 42774 - 42784. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Lemons, S. Barua, M. L. Abanto, W. Halfter, and M. L. Condic Adaptation of Sensory Neurons to Hyalectin and Decorin Proteoglycans J. Neurosci., May 18, 2005; 25(20): 4964 - 4973. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tani, N. Okino, N. Sueyoshi, and M. Ito Conserved Amino Acid Residues in the COOH-terminal Tail Are Indispensable for the Correct Folding and Localization and Enzyme Activity of Neutral Ceramidase J. Biol. Chem., July 9, 2004; 279(28): 29351 - 29358. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Lee, L. Chen, F. Paiwand, L. Cao, Y. Wu, R. Inman, M. E. Adams, and B. B. Yang Cleavage of the Carboxyl Tail from the G3 Domain of Aggrecan but Not Versican and Identification of the Amino Acids Involved in the Degradation J. Biol. Chem., June 14, 2002; 277(25): 22279 - 22288. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Nash, M. T. Deavers, and R. S. Freedman The Expression of Decorin in Human Ovarian Tumors Clin. Cancer Res., June 1, 2002; 8(6): 1754 - 1760. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. B. Schwartz and M. Domowicz Chondrodysplasias due to proteoglycan defects Glycobiology, April 1, 2002; 12(4): 57R - 68R. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wu, L. Chen, P.-S. Zheng, and B. B. Yang beta 1-Integrin-mediated Glioma Cell Adhesion and Free Radical-induced Apoptosis Are Regulated by Binding to a C-terminal Domain of PG-M/Versican J. Biol. Chem., March 29, 2002; 277(14): 12294 - 12301. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chen, Y. Wu, V. Lee, C. Kiani, M. E. Adams, Y. Yao, and B. B. Yang The Folded Modules of Aggrecan G3 Domain Exert Two Separable Functions in Glycosaminoglycan Modification and Product Secretion J. Biol. Chem., January 18, 2002; 277(4): 2657 - 2665. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-Z. Hu, J. Meng, and M. L. Dufau Isolation and Characterization of Two Novel Forms of the Human Prolactin Receptor Generated by Alternative Splicing of a Newly Identified Exon 11 J. Biol. Chem., October 26, 2001; 276(44): 41086 - 41094. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||